Please login to the form below

Spark Therapeutics

This page shows the latest Spark Therapeutics news and features for those working in and with pharma, biotech and healthcare.

Axovant drops last ‘legacy’ drug to focus on gene therapies

Pavan Cheruvu, Axovant CEO. Having attracted a gene therapy veteran to lead the programme in Fraser Wright – a co-founder and former chief technological officer at Spark Therapeutics - in June it

Latest news

Novartis gets EU nod for Luxturna gene therapy

Novartis secured rights to the gene therapy outside the US from its developer Spark Therapeutics in January, paying $100m upfront, shortly after Spark won FDA approval for the therapy as the ... Spark reported almost $9m in the third quarter from the
CHMP backs Spark’s Luxturna, but rejects Sarepta again

Contrasting fortunes for rare disease treatments. Spark Therapeutics looks set for approval of its eye disorder gene therapy Luxturna on both sides of the Atlantic after getting a green light from ... That was at the top-end of analyst expectations,
Bayer roll-out of haemophilia drug Jivi gathers pace

BioMarin and Spark Therapeutics.
Spark sputters on haemophilia A gene therapy safety scare

Investors compare data unfavourably with BioMarin rival. Gene therapy developer Spark Therapeutics has seen around $1bn carved off its value after it emerged that two patients in its haemophilia A gene ... Meanwhile, Spark says it has data showing that
Bluebird’s first gene therapy gets European fast track

recommendation, while Spark Therapeutics’ gene therapy Luxturna looks set to gain CHMP recommendation by the end of 2018.

More from news
Approximately 10 fully matching, plus 16 partially matching documents found.

Latest Intelligence

The European Medicines Agency: PRIME’d for access?

sales, and 6 are in the top 10 companies with Pfizer (with Spark Therapeutics), Novartis (by acquiring AveXis), Celgene (with Bluebird and through acquiring Juno Therapeutics), Sanofi, Roche and Merck all ... Those prices pale in comparison though when
Bluebird Bio: on the cusp of a gene therapy revolution

drugs, Novartis’ Kymriah and Gilead/Kite’s Yescarta and Spark Therapeutics’ gene therapy Luxturna all reaching the market last year. ... of a more stable adeno-associated virus (AAV) – which now forms the basis of Spark Therapeutics’ drugs and,
Health on instalment

For example, Luxturna maker Spark Therapeutics approached a commercial payer with a pay-for-performance option.
The rise of real-world evidence

Spark Therapeutics has a similar arrangement for its gene therapy. These agreements make real-world efficacy a requirement for full payment for a drug.
Deal Watch December 2016

and Bicycle Therapeutics at $1bn, and the Purdue Pharma-Exicure deal, at $790m. ... The size of the deals signed by AstraZeneca with Bicycle Therapeutics, by Spark with Selecta Biosciences and by Celgene with Evotec suggest that their technologies

More from intelligence
Approximately 0 fully matching, plus 7 partially matching documents found.

Latest appointments

Industry appointments

Sigilon has already reached certain milestones for its Living Therapeutics product platform, including its Afibromer technology, which represents a new class of breakthrough implantable biomaterials. ... Vivaldi has more than 25 years’ experience and

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Senior Account Manager: Competitive Salary Offered

Engagement Specialist, Healthcare Brand Communications, London, ...: circa £50K

Account Manager / Account Director: Competative

Engagement Expert, Healthcare Brand Communications, London: Excellent package

Account Manager / Senior Account Manager: 35, 000-40, 000

Senior Account Director development role to Business Director, H...: Excellent package

Account Director: Competitive Salary Offered

Business Director: Competitive Salary Offered

Technical Manager – Developer and Commercial Excellence, Healthc...: Excellent package

Editorial Assistant Medical Education Agency: £25, 000 - £26, 000

Senior Director – Healthcare PR – Global Agency: Salary TBC

Senior Medical Writer: Salary TBC

Global Business Development Director – Health Education: excellent commission

Account Director, Healthcare Marketing Agency: Salary TBC

Medical Writer: Salary TBC

Associate Director: £75, 000-90, 000

Home-based Senior Project Manager – Independent Med Ed: Salary TBC

Account Director – Healthcare Marketing – Berks: Salary TBC

Account Director – Health Policy – Global Agency: Salary TBC

Client Services Director – Medical Education Agency – North West...: Salary TBC

Account Director, Medical Education: Salary TBC

Senior Account Manager, Rare Diseases – Medical Communications, ...: Excellent package

PRINCIPAL MEDICAL WRITER > ETL - LONDON / NEW YORK/ HOME - ME...: Salary TBC

Subscribe to our email news alerts

PMHub

Add my company

Virgo Health

Virgo Health is an award-winning global healthcare communications and medical education agency comprising specialists with some of the best skills,...

Latest intelligence

The UK’s new five-year pricing agreement: Pharma has agreed to capped growth again - in exchange for uptake promises...
Digital applications are transforming the market access landscape: Organisations are leveraging new technology to implement a wider range of business models and, in essence, drive market access success by working smarter, faster and with greater economy....
Escaping the spin cycle of sub-optimal launch: ...